Gilead Sciences (NASDAQ:GILD)

buy sell

Why Investors Are Not Chasing Gilead Endlessly Higher

By any stretch of normal measurement in earnings season, Gilead Sciences Inc. (NASDAQ: GILD) should have been a rocketing stock on Wednesday. Gilead blew away earnings and revenue estimates. Its ...
Read Full Story »
biotech

Companies Betting on the Next 10 Blockbuster Drugs

The biotech sector has seen its valuations hit hard in many cases in 2014, but many investors remain excited about the future wave of big biotech drugs -- and big ...
Read Full Story »
DNA

UBS Top Stocks to Buy Working for Cancer Cures

Cancer is the leading cause of death globally, and a disease that touches almost every person in our nation one way or another. In a new research report, the Healthcare ...
Read Full Story »
biotech

An Earnings Tale of Two Biotechs: Gilead vs. Amgen

Gilead Sciences Inc. (NASDAQ: GILD) and Amgen Inc. (NASDAQ: AMGN) have both reported earnings. This is a definite difference in how the reports look, and it could throw a wild ...
Read Full Story »
Biotechnology word cloud

Biotech Earnings Previews: Amgen, Biogen Idec, Gilead, Celgene

Biotech stocks took it on the chin during the sell-off. In fact, biotech stocks may have even led the sell-off of momentum stocks in a reality check. The problem is ...
Read Full Story »
DNA

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside

Since March 4, the biotech index is off a massive 19%. There has been plenty of Wall Street speculation on why the sell-off was so violent, but at the end ...
Read Full Story »
stock symbol ticker

The 4 Stocks That Sank the Market

April 11, 2014: Markets opened lower on Friday with the S&P 500 and the Nasdaq Composite breaking into positive territory late in the morning. Unfortunately neither index could hold the ...
Read Full Story »
down market

Five Stocks That Have Fallen Most With the Lowest P/E Ratios

As the markets continue to unwind, some top-quality stocks are getting hit hard on a percentage basis and are looking very cheap. While it has become pretty obvious that portfolio ...
Read Full Story »
buy sell

Gilead Risks Beyond Just Merck: Serious Chart Violation Watch

Gilead Sciences Inc. (NASDAQ: GILD) may have been largely responsible for the drop in biotech stocks after politicians went after its drug costs, but an excessive multiyear performance above and ...
Read Full Story »
Biotechnology word cloud

Who Bucked the Short Interest Trend in Biotech Stocks?

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back in late March, and short sellers moved in on many ...
Read Full Story »
Boeing 747

Deutsche Bank Big Cap Stock Picks With Low P/E Ratios

After already having a strong bias towards low price-to earnings ratio (P/E) mega-cap stocks, the analysts at Deutsche Bank have ratcheted up their preference for that sector. In a new ...
Read Full Story »
research

Credit Suisse Says Grit Your Teeth and Buy Biotech

For the second time since late February, a huge run on the momentum, and specifically biotech, names hit the market last week. Again, the biotech benchmark took a huge 4% ...
Read Full Story »
Biotechnology word cloud

Stifel Says Strong Earnings Will Reignite Biotech Rally

When the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering and intense selling knocked a quick 17% off the index ...
Read Full Story »
Stock Split Image

Biotech Giants Now Priced Like Old World Drug Stocks

Most investors buying Big Pharma stocks these days are buying them for dividends and somewhat of a defensive position against stock market volatility. Investors who are buying biotechs generally are ...
Read Full Story »
DNA

Large Cap Biotechs Trading With Only Big Pharma P/E Ratios

The iShares Nasdaq Biotechnology (NASDAQ: IBB) exchange traded fund (ETF) has pulled back almost 17% since the February 25 peak, in a sell-off likened to the August 2011 debacle. Trading ...
Read Full Story »